C12N 2710/00034
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2710/00034 (Use of virus or viral component as vaccine) appears on 27 US grants and 48 published applications in this corpus.
Search patents in C12N- Granted patents
- 27
- Published applications
- 48
- Assignees
- 30
- Inventors
- 93
- Latest grant
- 18 Nov 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2006 | 0 | 2 |
| 2007 | 0 | 0 |
| 2008 | 1 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 0 | 1 |
| 2013 | 1 | 3 |
| 2014 | 3 | 4 |
| 2015 | 1 | 5 |
| 2016 | 5 | 3 |
| 2017 | 2 | 6 |
| 2018 | 2 | 6 |
| 2019 | 4 | 2 |
| 2020 | 2 | 3 |
| 2021 | 3 | 2 |
| 2022 | 1 | 1 |
| 2023 | 0 | 0 |
| 2024 | 1 | 2 |
| 2025 | 1 | 4 |
| 2026 | 0 | 3 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Gallid alphaherpesvirus 3 (MDV-2), a viral vector against different avian pathogens: a new vaccination strategy in the poultry industry18 Nov 2025US 12,473,572 B1FarmacolóGicos Veterinarios S.A.C.
- Muramyl peptide derivatives5 Nov 2024US 12,134,664 B2Bharat Biotech International Limited
- Promoters1 Mar 2022US 11,261,464 B2
- CTLA-4 antibodies and uses thereof28 Dec 2021US 11,208,483 B2Shanghai Kanda Biotechnology Co., Ltd.
- Treatment of infection15 Jun 2021US 11,033,618 B2
- Modified long peptides suitable for use in immunisation16 Jul 2026US 2026/0200990 A1Isabella Pharma B.V.
- Materials and methods to treat epstein-barr virus (ebv) and ebv-induced diseases28 May 2026US 2026/0144862 A1Medizinische Universität Wien
- Culture method for fish cells and cell culture medium used therein, and oral vaccine for fish22 Jan 2026US 2026/0021174 A1Bio Science Co., Ltd.
- Drug-delivery composition including plant-derived nanovesicles as active ingredients3 Jul 2025US 2025/0213677 A1Andong National University Industry-Academic Cooperation Foundation
- Vaccine development platform using plant-secreted nano-vesicles for delivery of recombinant protein and mrna3 Jul 2025US 2025/0213678 A1Andong National University Industry-Academic Cooperation Foundation
Most cited
By later US patents
- Compositions and methods for the treatment or prevention of hepatitis B virus infection21US 8,722,054 B2GlobeImmune, Inc. · 2014
- Methods for constructing antibiotic resistance free vaccines10US 8,906,664 B2The Trustees of the University of Pennsylvania · 2014
- Methods for constructing antibiotic resistance free vaccines10US 9,492,527 B2The Trustees of the University of Pennsylvania · 2016
- Methods for constructing antibiotic resistance free vaccines10US 9,700,608 B22017
- Yeast-based therapeutic for chronic hepatitis B infection5US 8,877,205 B2GlobeImmune, Inc. · 2014